T-cell large granular lymphocyte leukemia: Difference between revisions
No edit summary |
No edit summary |
||
(14 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{SI}} | ||
{{CMG}} {{AE}} {{RT}} {{MV}} | |||
| | |||
{{SK}} LGL leukemia; Tγ-lymphoproliferative disorder; T-cell chronic lymphocytic leukemia; proliferation of large granular lymphocytes (LGLs) | |||
==Overview== | |||
T-cell large granular lymphocyte leukemia (also known as T-GLL) is a rare type of [[leukemia]] that exhibits an unexplained, [[Chronic (medical)|chronic]] (> 6 months) elevation in large [[Granule (cell biology)|granular]] [[lymphocytes]] (LGLs) in the [[peripheral blood]]. T-cell large granular lymphocyte leukemia was first discovered by McKenna, in 1977. T-cell large granular lymphocyte leukemia may be [[Classification|classified]] into 2 groups: T-cell large granular lymphocyte leukemia (T-LGL) and [[Natural Killer T cell|natural-killer (NK)]] granular lymphocyte leukemia (NK-LGL). The [[pathogenesis]] of T-cell large granular lymphocyte leukemia is characterized by the involvement of [[Cytotoxic T cell|cytotoxic T cells]]. The postulated [[Cell (biology)|cells]] of origin of T-LGL leukemia are transformed [[CD8+ T cells|CD8+]] [[T cell|T-cells]] with clonal rearrangements of β chain [[T cell receptor|T-cell receptor]] [[Gene|genes]] for the majority of cases and a CD8- [[T cell|T-cell]] with clonal rearrangements of γ chain [[T-cell receptor]] [[Gene|genes]] for a minority of cases. The [[Molecule|molecular]] [[pathogenesis]] of T-cell large granular lymphocyte leukemia is characterized by the disregulation of [[Signal transduction|signaling pathways]], such as: FAS/FAS-L, phosphatidylinositol-3 kinase (PI3K), and mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK). [[Patient|Patients]] of all age groups may develop T-cell large granular lymphocyte leukemia. T-cell large granular lymphocyte leukemia is more commonly observed among middle aged [[Adult|adults]]. [[Laboratory]] findings consistent with the [[diagnosis]] of T-cell large granular lymphocyte leukemia include [[neutropenia]], [[anemia]], [[hypergammaglobulinemia]], and [[lymphocytosis]] (most common). The [[diagnosis]] of T-cell large granular lymphocyte leukemia is made when the following diagnostic criteria is met: clonal rearrangements of the [[T-cell receptor|T-cell receptor (TCR)]] [[gene]], [[chronic]] (> 6 months) elevation in large granular lymphocytes (LGLs) in the [[peripheral blood]], large granular [[lymphocyte]] count greater than 2.0 × 109/L, and [[lymphocytosis]] (typically 2-20x109/L). The mainstay of [[therapy]] for T-cell large granular lymphocyte leukemia is [[Chemotherapy|targeted-chemotherapy]]. Initial [[therapy]] for [[Patient|patients]] with T-cell large granular lymphocyte leukemia includes [[Corticosteroid|corticosteroids]] and [[methotrexate]]. [[Alemtuzumab]] and [[tipifarnib]] are the treatment of choice for [[Patient|patients]] with [[refractory]] T-cell large granular lymphocytic leukemia. | |||
==Historical Perspective== | |||
*T-cell large granular lymphocyte leukemia was first discovered by McKenna, in 1977.<ref name="pmid22830400">{{cite journal |vauthors=Leblanc F, Zhang D, Liu X, Loughran TP |title=Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets |journal=Future Oncol |volume=8 |issue=7 |pages=787–801 |year=2012 |pmid=22830400 |pmc=3464048 |doi=10.2217/fon.12.75 |url=}}</ref> | |||
==Classification== | |||
T-cell large granular lymphocyte leukemia may be [[Classification|classified]] into 2 groups:<ref name="lam1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12876667&query_hl=10&itool=pubmed_ExternalLink] | |||
Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." '''Semin Hematol'''. 2003 Jul;40(3):185-95. PMID: 12876667</ref> | |||
* T-cell large granular lymphocyte leukemia (T-LGL) | |||
* [[Natural-killer]] (NK) granular lymphocyte leukemia (NK-LGL) | |||
==Pathophysiology== | |||
*The [[pathogenesis]] of T-cell large granular lymphocyte leukemia is characterized by the involvement of [[Cytotoxic T cell|cytotoxic T cells]]. | |||
*The postulated [[Cell (biology)|cells]] of origin of T-LGL leukemia are transformed [[Cytotoxic T cell|CD8+ T-cell]] with clonal rearrangements of β chain [[T-cell receptor]] [[Gene|genes]] for the majority of cases and a CD8- [[T cell|T-cell]] with clonal rearrangements of γ chain [[T-cell receptor]] [[Gene|genes]] for a minority of cases.<ref name="lam1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12876667&query_hl=10&itool=pubmed_ExternalLink] | |||
Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." '''Semin Hematol'''. 2003 Jul;40(3):185-95. PMID: 12876667</ref> | |||
*The [[leukemia]] [[Cell (biology)|cells]] of T-cell large granular lymphocyte leukemia can be found in [[peripheral blood]], [[bone marrow]], [[spleen]], and [[liver]]. [[Lymph node|Nodal]] involvement is rare. | |||
*The [[Molecule|molecular]] [[pathogenesis]] of T-cell large granular lymphocyte leukemia is characterized by the disregulation of [[Signal transduction|signaling pathways]], such as: | |||
:*FAS/FAS-L | |||
:*[[Phosphoinositide 3-kinase|Phosphatidylinositol-3 kinase (PI3K)]], | |||
:*[[Mitogen-activated protein kinase]]/[[Extracellular signal-regulated kinases|extracellular signal-regulated kinase]] ([[Mitogen-activated protein kinase|MAPK]]/[[Extracellular signal-regulated kinases|ERK]]) | |||
*The increased expression of [[STAT3]] has been associated with the development of T-cell large granular lymphocyte leukemia, involving the [[janus kinase]] family pathway. | |||
*On [[microscopic]] [[Histopathology|histopathological]] [[analysis]], characteristic findings of T-cell large granular lymphocyte leukemia include: | |||
:*[[Cancer|Neoplastic]] [[Lymphocyte|lymphocytes]] (large in size) | |||
:*Presence of [[azurophilic granules]] (contains [[Protein|proteins]] involved in [[Lysis|cell lysis]] such as [[perforin]] and [[granzyme B]]) | |||
:*[[Bone marrow]] involvement in this [[disease]] is often present, but to a variable extent | |||
:*The [[Lymphocyte|lymphocytic]] infiltrate is usually [[interstitial]], but a [[nodular]] pattern rarely occurs | |||
*On [[immunohistochemistry]], characteristic findings of T-cell large granular lymphocyte leukemia include: | |||
:*Positive [[perforin]] | |||
:*Positive [[TIA-1]] | |||
:*Positive [[granzyme B]] | |||
== | ==Causes== | ||
Common causes of T-cell large granular lymphocyte leukemia include:<ref name="pmid22830400">{{cite journal |vauthors=Leblanc F, Zhang D, Liu X, Loughran TP |title=Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets |journal=Future Oncol |volume=8 |issue=7 |pages=787–801 |year=2012 |pmid=22830400 |pmc=3464048 |doi=10.2217/fon.12.75 |url=}}</ref> | |||
* [[Autoimmune disorders]] such as: | |||
** [[Systemic lupus erythematosus|Systemic lupus erythematosus (SLE or lupus)]] | |||
** [[Hashimoto's Thyroiditis|Hashimoto’s thyroiditis]] | |||
** [[Sjogren’s syndrome]] | |||
== | ==Differentiating T-cell Large Granular Lymphocyte Leukemia from Other Diseases== | ||
*T-cell large granular lymphocyte leukemia must be differentiated from other [[Disease|diseases]] that cause recurrent [[Infection|infections]], [[fatigue]], and night [[fever]], such as: | |||
:*Precursor T lymphoblastic leukemia/[[lymphoma]] | |||
:*[[Mycosis fungoides]] | |||
:*[[HIV AIDS]] | |||
:*[[Burkitt's lymphoma|Burkitt lymphoma]] | |||
== | ==Epidemiology and Demographics== | ||
* T-cell large granular lymphocyte leukemia is a rare form of [[leukemia]], comprising 2 - 3% of all cases of [[Chronic (medical)|chronic]] [[lymphoproliferative disorders]]. | |||
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids= | |||
===Age=== | |||
" | *[[Patients]] of all age groups may develop T-cell large granular lymphocyte leukemia. | ||
*T-cell large granular lymphocyte leukemia is more commonly observed among middle aged [[Adult|adults]].<ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | |||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref> | |||
=== | ===Gender=== | ||
*T-cell large granular lymphocyte leukemia affects [[Male|men]] and [[Female|women]] equally. | |||
=== | ===Race=== | ||
*There is no racial predilection for T-cell large granular lymphocyte leukemia. | |||
== | ==Risk Factors== | ||
[[ | *The most common [[risk factor]] in the development of T-cell large granular lymphocyte leukemia is exposure to [[Radiation therapy|radiation]].<ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | ||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref> | |||
== | == Natural History, Complications and Prognosis== | ||
T- | *The majority of [[Patient|patients]] with T-cell large granular lymphocyte leukemia may be initially [[asymptomatic]]. | ||
*Early clinical features include [[fever]], [[Sleep hyperhidrosis|night sweats]], and [[weight loss]]. | |||
*If left untreated, [[Patient|patients]] with T-cell large granular lymphocyte leukemia may progress to develop [[Infection|infections]]. | |||
*Common [[complications]] of T-cell large granular lymphocyte leukemia include:<ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | |||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref> | |||
:*[[Bone marrow suppression|Bone marrow failure]] [[Disorder (medicine)|disorders]] | |||
:*[[Myelodysplastic syndrome]] | |||
:*[[Aplastic anemia]] | |||
:*[[Paroxysmal nocturnal hemoglobinuria]] | |||
*[[Prognosis]] is generally good, and the 5 year survival rate of [[patients]] with T-cell large granular lymphocyte leukemia is approximately 89%.<ref name="lam1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12876667&query_hl=10&itool=pubmed_ExternalLink] | |||
Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." '''Semin Hematol'''. 2003 Jul;40(3):185-95. PMID: 12876667</ref> | |||
== Diagnosis == | |||
===Diagnostic Study of Choice=== | |||
The [[diagnosis]] of T-cell large granular lymphocyte leukemia is made when the following diagnostic criteria is met:<ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | |||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref> | |||
* Clonal rearrangements of the [[T-cell receptor|T-cell receptor (TCR)]] [[gene]] | |||
* [[Chronic (medical)|Chronic]] (> 6 months) elevation in large granular lymphocytes (LGLs) in the [[peripheral blood]] | |||
* Large [[Granule (cell biology)|granular]] [[lymphocyte]] count greater than 2.0 × 109/L | |||
* [[Lymphocytosis]] (typically 2-20x109/L) | |||
== | === Symptoms === | ||
*T-cell large granular lymphocyte leukemia may be initially [[asymptomatic]]. | |||
* | *[[Symptom|Symptoms]] of T-cell large granular lymphocyte leukemia may include the following:<ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | ||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref> | |||
** Generalized weakness and [[Fatigue (physical)|fatigue]] | |||
** [[Anorexia]] | |||
**[[Arthralgia|Joint pain]] | |||
** [[Sleep hyperhidrosis|Night sweats]] | |||
** [[Epistaxis]] | |||
** [[Bone pain]] | |||
** [[Dyspnea|Difficulty breathing]] | |||
== | === Physical Examination === | ||
*[[Patient|Patients]] with T-cell large granular lymphocyte leukemia usually appear [[Pallor|pale]] and [[Malnutrition|malnourished]]. | |||
* [[ | *[[Physical examination]] may be remarkable for:<ref name="lam2">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10761014&query_hl=22&itool=pubmed_ExternalLink] | ||
* | |||
Lamy T, Loughran TP. "Large Granular Lymphocyte Leukemia." '''Cancer Control'''. 1998 Jan;5(1):25-33. PMID: 10761014</ref><ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | Lamy T, Loughran TP. "Large Granular Lymphocyte Leukemia." '''Cancer Control'''. 1998 Jan;5(1):25-33. PMID: 10761014</ref><ref name="cha1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3490288&query_hl=6&itool=pubmed_ExternalLink] | ||
Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref><ref name="pan1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2403836&query_hl=8&itool=pubmed_ExternalLink] | Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." '''Blood'''. 1986 Nov;68(5):1142-53. PMID: 3490288</ref><ref name="pan1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2403836&query_hl=8&itool=pubmed_ExternalLink] | ||
Pandolfi F, Loughran TP Jr, Starkebaum G, Chisesi T, Barbui T, Chan WC, Brouet JC, De Rossi G, McKenna RW, Salsano F, ''et al.'' "Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study." '''Cancer'''. 1990 Jan 15;65(2):341-8. PMID: 2403836</ref><ref name="lam1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12876667&query_hl=10&itool=pubmed_ExternalLink] | Pandolfi F, Loughran TP Jr, Starkebaum G, Chisesi T, Barbui T, Chan WC, Brouet JC, De Rossi G, McKenna RW, Salsano F, ''et al.'' "Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study." '''Cancer'''. 1990 Jan 15;65(2):341-8. PMID: 2403836</ref><ref name="lam1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12876667&query_hl=10&itool=pubmed_ExternalLink] | ||
Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." '''Semin Hematol'''. 2003 Jul;40(3):185-95. PMID: 12876667</ref> | Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." '''Semin Hematol'''. 2003 Jul;40(3):185-95. PMID: 12876667</ref> | ||
* | :*[[Heart murmur|Cardiac flow murmur]] | ||
:*High-grade [[fever]] | |||
:*[[Hepatomegaly]] | |||
:*[[Splenomegaly]] | |||
=== | === Laboratory Findings === | ||
=== | [[Medical laboratory|Laboratory]] findings consistent with the [[diagnosis]] of T-cell large granular lymphocyte leukemia include: | ||
* [[ | *[[Neutropenia]] | ||
*[[Anemia]] | |||
*[[Hypergammaglobulinemia]] | |||
*[[Lymphocytosis]] (most common) | |||
===Imaging Findings=== | |||
*There are no specific [[imaging]] findings associated with T-cell large granular lymphocyte leukemia. | |||
=== | === Other Diagnostic Studies === | ||
* [[ | *T-cell large granular lymphocyte leukemia may also be [[Diagnosis|diagnosed]] using the following studies: | ||
'''Immunophenotyping''' | |||
*The following table demonstrates common [[Immunophenotyping|immunophenotype]] findings. | |||
* | *The [[Cancer|neoplastic]] [[Cell (biology)|cells]] of this [[disease]] display a mature [[T-cell]] [[immunophenotype]], with the majority of cases showing a [[CD4]]-/[[CD8]]+ [[T cell|T-cell]] subset [[immunophenotype]] versus other permutations of those markers. Variable expression of [[CD11b]], [[CD56]], and [[CD57]] are observed. | ||
* The | |||
{| border="1" cellpadding="5" cellspacing="0" | {| border="1" cellpadding="5" cellspacing="0" | ||
Line 81: | Line 135: | ||
! Type || Immunophenotype | ! Type || Immunophenotype | ||
|- | |- | ||
| rowspan="1"| Common type (80% of cases) | | rowspan="1" | Common type (80% of cases) | ||
| colspan="1" align="center"| [[CD3]]+, [[TCR]]αβ+, [[CD4]]-, [[CD8]]+ | | colspan="1" align="center" | [[CD3]]+, [[TCR]]αβ+, [[CD4]]-, [[CD8]]+ | ||
|- | |- | ||
| rowspan="3" align="center" | Rare variants | | rowspan="3" align="center" | Rare variants | ||
Line 92: | Line 146: | ||
|} | |} | ||
==Treatment== | '''Peripheral blood smear''' | ||
[[ | *Large [[Cancer|neoplastic]] [[Lymphocyte|lymphocytes]] | ||
*[[Azurophil|Azurophilic]] [[Granule (cell biology)|granules]] | |||
== Treatment == | |||
=== Medical Therapy === | |||
*The mainstay of [[therapy]] for T-cell large granular lymphocyte leukemia is [[Chemotherapy|targeted-chemotherapy]]. | |||
*Initial [[therapy]] for [[Patient|patients]] with T-cell large granular lymphocyte leukemia may include: | |||
:*[[Corticosteroid|Corticosteroids]] | |||
:*[[Methotrexate]] | |||
*[[Alemtuzumab]] and [[tipifarnib]] are the treatment of choice for [[Patient|patients]] with [[refractory]] T-cell large granular lymphocytic leukemia. | |||
=== Prevention === | |||
*There are no [[Prevention (medical)|primary preventive measures]] available for T-cell large granular lymphocyte leukemia. | |||
*Once [[Diagnosis|diagnosed]] and successfully treated, [[Patient|patients]] with T-cell large granular lymphocyte leukemia are followed-up every 3, 6 or 12 months. | |||
*Follow-up [[Test|testing]] includes [[complete blood count]], [[physical examination]], and [[Blood film|peripheral blood smear]]. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: Oncology]] | |||
[[Category:Oncology | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] |
Latest revision as of 17:38, 30 April 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [5] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [6] Maria Fernanda Villarreal, M.D. [7]
Synonyms and keywords: LGL leukemia; Tγ-lymphoproliferative disorder; T-cell chronic lymphocytic leukemia; proliferation of large granular lymphocytes (LGLs)
Overview
T-cell large granular lymphocyte leukemia (also known as T-GLL) is a rare type of leukemia that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood. T-cell large granular lymphocyte leukemia was first discovered by McKenna, in 1977. T-cell large granular lymphocyte leukemia may be classified into 2 groups: T-cell large granular lymphocyte leukemia (T-LGL) and natural-killer (NK) granular lymphocyte leukemia (NK-LGL). The pathogenesis of T-cell large granular lymphocyte leukemia is characterized by the involvement of cytotoxic T cells. The postulated cells of origin of T-LGL leukemia are transformed CD8+ T-cells with clonal rearrangements of β chain T-cell receptor genes for the majority of cases and a CD8- T-cell with clonal rearrangements of γ chain T-cell receptor genes for a minority of cases. The molecular pathogenesis of T-cell large granular lymphocyte leukemia is characterized by the disregulation of signaling pathways, such as: FAS/FAS-L, phosphatidylinositol-3 kinase (PI3K), and mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK). Patients of all age groups may develop T-cell large granular lymphocyte leukemia. T-cell large granular lymphocyte leukemia is more commonly observed among middle aged adults. Laboratory findings consistent with the diagnosis of T-cell large granular lymphocyte leukemia include neutropenia, anemia, hypergammaglobulinemia, and lymphocytosis (most common). The diagnosis of T-cell large granular lymphocyte leukemia is made when the following diagnostic criteria is met: clonal rearrangements of the T-cell receptor (TCR) gene, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood, large granular lymphocyte count greater than 2.0 × 109/L, and lymphocytosis (typically 2-20x109/L). The mainstay of therapy for T-cell large granular lymphocyte leukemia is targeted-chemotherapy. Initial therapy for patients with T-cell large granular lymphocyte leukemia includes corticosteroids and methotrexate. Alemtuzumab and tipifarnib are the treatment of choice for patients with refractory T-cell large granular lymphocytic leukemia.
Historical Perspective
- T-cell large granular lymphocyte leukemia was first discovered by McKenna, in 1977.[1]
Classification
T-cell large granular lymphocyte leukemia may be classified into 2 groups:[2]
- T-cell large granular lymphocyte leukemia (T-LGL)
- Natural-killer (NK) granular lymphocyte leukemia (NK-LGL)
Pathophysiology
- The pathogenesis of T-cell large granular lymphocyte leukemia is characterized by the involvement of cytotoxic T cells.
- The postulated cells of origin of T-LGL leukemia are transformed CD8+ T-cell with clonal rearrangements of β chain T-cell receptor genes for the majority of cases and a CD8- T-cell with clonal rearrangements of γ chain T-cell receptor genes for a minority of cases.[2]
- The leukemia cells of T-cell large granular lymphocyte leukemia can be found in peripheral blood, bone marrow, spleen, and liver. Nodal involvement is rare.
- The molecular pathogenesis of T-cell large granular lymphocyte leukemia is characterized by the disregulation of signaling pathways, such as:
- The increased expression of STAT3 has been associated with the development of T-cell large granular lymphocyte leukemia, involving the janus kinase family pathway.
- On microscopic histopathological analysis, characteristic findings of T-cell large granular lymphocyte leukemia include:
- Neoplastic lymphocytes (large in size)
- Presence of azurophilic granules (contains proteins involved in cell lysis such as perforin and granzyme B)
- Bone marrow involvement in this disease is often present, but to a variable extent
- The lymphocytic infiltrate is usually interstitial, but a nodular pattern rarely occurs
- On immunohistochemistry, characteristic findings of T-cell large granular lymphocyte leukemia include:
- Positive perforin
- Positive TIA-1
- Positive granzyme B
Causes
Common causes of T-cell large granular lymphocyte leukemia include:[1]
- Autoimmune disorders such as:
Differentiating T-cell Large Granular Lymphocyte Leukemia from Other Diseases
- T-cell large granular lymphocyte leukemia must be differentiated from other diseases that cause recurrent infections, fatigue, and night fever, such as:
- Precursor T lymphoblastic leukemia/lymphoma
- Mycosis fungoides
- HIV AIDS
- Burkitt lymphoma
Epidemiology and Demographics
- T-cell large granular lymphocyte leukemia is a rare form of leukemia, comprising 2 - 3% of all cases of chronic lymphoproliferative disorders.
Age
- Patients of all age groups may develop T-cell large granular lymphocyte leukemia.
- T-cell large granular lymphocyte leukemia is more commonly observed among middle aged adults.[3]
Gender
Race
- There is no racial predilection for T-cell large granular lymphocyte leukemia.
Risk Factors
- The most common risk factor in the development of T-cell large granular lymphocyte leukemia is exposure to radiation.[3]
Natural History, Complications and Prognosis
- The majority of patients with T-cell large granular lymphocyte leukemia may be initially asymptomatic.
- Early clinical features include fever, night sweats, and weight loss.
- If left untreated, patients with T-cell large granular lymphocyte leukemia may progress to develop infections.
- Common complications of T-cell large granular lymphocyte leukemia include:[3]
- Prognosis is generally good, and the 5 year survival rate of patients with T-cell large granular lymphocyte leukemia is approximately 89%.[2]
Diagnosis
Diagnostic Study of Choice
The diagnosis of T-cell large granular lymphocyte leukemia is made when the following diagnostic criteria is met:[3]
- Clonal rearrangements of the T-cell receptor (TCR) gene
- Chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood
- Large granular lymphocyte count greater than 2.0 × 109/L
- Lymphocytosis (typically 2-20x109/L)
Symptoms
- T-cell large granular lymphocyte leukemia may be initially asymptomatic.
- Symptoms of T-cell large granular lymphocyte leukemia may include the following:[3]
- Generalized weakness and fatigue
- Anorexia
- Joint pain
- Night sweats
- Epistaxis
- Bone pain
- Difficulty breathing
Physical Examination
- Patients with T-cell large granular lymphocyte leukemia usually appear pale and malnourished.
- Physical examination may be remarkable for:[4][3][5][2]
- Cardiac flow murmur
- High-grade fever
- Hepatomegaly
- Splenomegaly
Laboratory Findings
Laboratory findings consistent with the diagnosis of T-cell large granular lymphocyte leukemia include:
- Neutropenia
- Anemia
- Hypergammaglobulinemia
- Lymphocytosis (most common)
Imaging Findings
- There are no specific imaging findings associated with T-cell large granular lymphocyte leukemia.
Other Diagnostic Studies
- T-cell large granular lymphocyte leukemia may also be diagnosed using the following studies:
Immunophenotyping
- The following table demonstrates common immunophenotype findings.
- The neoplastic cells of this disease display a mature T-cell immunophenotype, with the majority of cases showing a CD4-/CD8+ T-cell subset immunophenotype versus other permutations of those markers. Variable expression of CD11b, CD56, and CD57 are observed.
Type | Immunophenotype |
---|---|
Common type (80% of cases) | CD3+, TCRαβ+, CD4-, CD8+ |
Rare variants | CD3+, TCRαβ+, CD4+, CD8- |
CD3+, TCRαβ+, CD4+, CD8+ | |
CD3+, TCRγδ+, CD4 and CD8 variable |
Peripheral blood smear
Treatment
Medical Therapy
- The mainstay of therapy for T-cell large granular lymphocyte leukemia is targeted-chemotherapy.
- Initial therapy for patients with T-cell large granular lymphocyte leukemia may include:
- Alemtuzumab and tipifarnib are the treatment of choice for patients with refractory T-cell large granular lymphocytic leukemia.
Prevention
- There are no primary preventive measures available for T-cell large granular lymphocyte leukemia.
- Once diagnosed and successfully treated, patients with T-cell large granular lymphocyte leukemia are followed-up every 3, 6 or 12 months.
- Follow-up testing includes complete blood count, physical examination, and peripheral blood smear.
References
- ↑ 1.0 1.1 Leblanc F, Zhang D, Liu X, Loughran TP (2012). "Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets". Future Oncol. 8 (7): 787–801. doi:10.2217/fon.12.75. PMC 3464048. PMID 22830400.
- ↑ 2.0 2.1 2.2 2.3 [1] Lamy T, Loughran TP Jr. "Clinical features of large granular lymphocyte leukemia." Semin Hematol. 2003 Jul;40(3):185-95. PMID: 12876667
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 [2] Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF. "Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes." Blood. 1986 Nov;68(5):1142-53. PMID: 3490288
- ↑ [3] Lamy T, Loughran TP. "Large Granular Lymphocyte Leukemia." Cancer Control. 1998 Jan;5(1):25-33. PMID: 10761014
- ↑ [4] Pandolfi F, Loughran TP Jr, Starkebaum G, Chisesi T, Barbui T, Chan WC, Brouet JC, De Rossi G, McKenna RW, Salsano F, et al. "Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study." Cancer. 1990 Jan 15;65(2):341-8. PMID: 2403836